Hikal (India) Today
| HIKAL Stock | 252.89 8.72 3.57% |
PerformanceWeakest
| Odds Of DistressTiny
|
Hikal is selling at 252.89 as of the 5th of December 2025; that is 3.57 percent increase since the beginning of the trading day. The stock's open price was 244.17. Hikal has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 6th of September 2025 and ending today, the 5th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Hikal is entity of India. It is traded as Stock on NSE exchange. The company has 123.3 M outstanding shares. More on Hikal Limited
Moving against Hikal Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Hikal Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hikal's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hikal or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Founder Chairman | Jai Hiremath | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) | ||||
Hikal's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Hikal's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsHikal can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hikal's financial leverage. It provides some insight into what part of Hikal's total assets is financed by creditors.
| |||||
Hikal Limited (HIKAL) is traded on National Stock Exchange of India in India and employs 2,062 people. Hikal is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 31.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hikal's market, we take the total number of its shares issued and multiply it by Hikal's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hikal Limited operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 123.3 M outstanding shares.
Hikal Limited has accumulated about 4.86 M in cash with 2.8 B of positive cash flow from operations.
Check Hikal Probability Of Bankruptcy
Ownership AllocationHikal Limited has a total of 123.3 Million outstanding shares. Hikal retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.08 (percent) of Hikal outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hikal Ownership Details
Hikal Limited Risk Profiles
Although Hikal's alpha and beta are two of the key measurements used to evaluate Hikal's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.27 | |||
| Standard Deviation | 1.88 | |||
| Variance | 3.53 | |||
| Risk Adjusted Performance | (0.02) |
Hikal Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hikal without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Hikal Corporate Management
Elected by the shareholders, the Hikal's board of directors comprises two types of representatives: Hikal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikal. The board's role is to monitor Hikal's management team and ensure that shareholders' interests are well served. Hikal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dharmesh Panchal | Chief Officer | Profile | |
| Rajasekhar Reddy | WholeTime Officer | Profile | |
| Rajasekhar Chintakindi | Company Officer | Profile | |
| Devanathan | Pharmaceuticals Quality | Profile |
Other Information on Investing in Hikal Stock
Hikal financial ratios help investors to determine whether Hikal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikal with respect to the benefits of owning Hikal security.